Therefore, as an NLRP3 inhibitor, which has been funded by the Michael J. Fox Foundation and FightMND to study RRx-001 in Parkinson’s disease and amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), IL-1β and IL-18 are potential biomarkers of activity of RRx-001 in GBM; however, as this was, first and foremost, a safety and tolerability trial, IL-1β and IL-18 levels were not measured. The gene discussed is NLRP3; the disease is glioblastoma.